Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

ABSTRACT:

Background

Clinical features of patients with castration-resistant prostate cancer (CRPC) are characterized by a high incidence of bone metastases, which are associated with impairment of quality of life, pain, skeletal-related events (SREs), and a negative impact on prognosis. Advances in the understanding of cancer cell-bone stroma interactions and molecular mechanisms have recently permitted the development of new agents.

Purpose

We review the merits, applications, and limitations of emerging data sets on bone-metastatic CRPC with a focus on radium-223, an α-emitting radiopharmaceutical, and its use in therapy for this disease.

Methods

References for this review were identified through searches of PubMed and Medline databases, and only papers published in English w

SUBMITTER: Ryan CJ 

PROVIDER: S-EPMC4200991 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature